NASDAQHealth CareBiotechnologySnapshot 2026-07-23
Reading DARE? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. The company is currently loss-making and faces volatility in management and performance, but it operates in a sector with favorable tailwinds.
The market appears to have a low fragility tier, indicating that it does not expect significant disruptions. However, the premium valuation compared to peers suggests that some positive expectations are already priced in.
Management has emphasized launching new products, but execution remains mixed. The near-term risk is heightened, with a 44% probability of missing expectations due to the company's smaller size and the industry's high miss rate.
The long-term thesis hinges on the successful launch of new products and the performance of sector bellwethers like VRTX, REGN, and ARGX. Any negative guidance or performance from these companies could impact DARE significantly.
In the next 1 to 3 years, DARE's performance will depend on product launches and broader sector trends. Not investment advice.
The most important moves since the prior daily snapshot.
risk label changed from 'high' to 'elevated'.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Earnings results will show how well the company is performing. A beat could improve outlook.
Confirms one read:Q2 earnings beat analyst expectations by more than 10%.
Confirms the other:Q2 earnings miss analyst expectations by more than 10%.
Why it matters: The company got a notice about possible delisting. This affects investor trust and stock value.
Confirms:Dare Bioscience fixes the delisting notice and meets Nasdaq rules.
Disproves:Dare Bioscience fails to resolve the delisting notice, leading to actual delisting.
Why it matters: Earnings beats show strong performance. Consistent beats can improve investor confidence.
Confirms:Next earnings report shows earnings per share above analyst estimates by at least 10%.
Disproves:The next earnings report will show earnings per share lower than analyst estimates.
Why it matters: The launch of DARE to PLAY marks a key revenue milestone for the company. Success here could signal strong market demand for women's health products.
Confirms:DARE to PLAY generates over $100K in revenue in Q3 2026.
Disproves:DARE to PLAY fails to generate any revenue in Q3 2026.
Why it matters: The launch of Flora Sync LF5 is important for the company. It helps them enter the consumer health market. Early sales may show if people like their products.
Confirms:Flora Sync LF5 generates over $100K in revenue in Q2 2026.
Disproves:Flora Sync LF5 fails to generate any revenue in Q2 2026.
Why it matters: Funding from Regulation A offerings is key. It shows the company's financial health.
Confirms one read:Dare finishes more Regulation A offerings. These are worth over $1 million.
Confirms the other:Dare fails to complete any new Regulation A offerings in the next quarter.
Why it matters: If healthcare sector growth picks up, it could benefit Dare's performance.
Confirms:Healthcare sector revenue growth speeds up to 10% or more.
Disproves:Healthcare sector revenue growth keeps slowing below current levels.
Why it matters: Finishing enrollment is an important step for FDA approval. It shows progress in creating a new contraceptive option.
Confirms:Enrollment for the Ovaprene trial reaches 2,500 cycles by the end of 2026.
Disproves:Enrollment fails to reach 2,500 cycles by the end of 2026.
